Skip to main content

Tegavivint

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

  • RegistryNCT05755087
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRelapsed or Refractory Large B-Cell Lymphoma
  • SponsorLapo Alinari
How Tegavivint worksNCT057550871 min

What the film says

Read the transcript

This trial is for adults with large B cell lymphoma that has come back or not responded to treatment.

The idea: tegavivint is a drug given by vein that may stop cancer cells from growing by blocking some of the enzymes they need. Giving it may help control the disease.

The study looks at safety, side effects, and the best dose.

This phase 1 study plans 18 patients. At the Ohio State University Comprehensive Cancer Center in Columbus, Lapo Alinari leads it.

Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

Undergo bone marrow biopsy and aspiration

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of tegavivint in patients with relapsed/refractory c-Myc overexpressing large B-cell lymphoma. II. To determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of tegavivint. SECONDARY OBJECTIVES: I. To determine the preliminary efficacy of tegavivint in patients with relapsed/refractory c-Myc overexpressing large B-cell lymphoma. II. To determine the pharmacokinetic parameters of tegavivint.

EXPLORATORY OBJECTIVES: I. To correlate response to tegavivint with the presence of MYC, FBW7 and SKP2 mutations. II. To correlate response to tegavivint with TBL1 and c-Myc expression assessed by standard IHC on archived tumor biopsy. III. To determine the effects of tegavivint on immune cell subsets viability and function. OUTLINE: This is a dose-escalation study of tegavivint. Patients receive tegavivint intravenously (IV) on study.

The study

How the trial runs.

This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Increased expression of MYC (>= 40%) and BCL2 (>= 50%) by immunohistochemistry (IHC) or
  • Presence of isolated MYC translocation Or
  • Relapsed/refractory histologically confirmed high-grade B-cell lymphoma (HGBCL) (double hit [DH] and triple hit [TH]) with translocations of MYC and BCL2 and/or BCL6 Or
  • Histologic transformation of indolent non-Hodgkin's lymphoma (NHL) to DLBCL

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.